Is Johnson & Johnson still a Dividend King after spinning off Kenvue?

Yes. J&J has maintained its Dividend King status through the Kenvue spinoff. The company has raised its dividend for over 60 consecutive years as of 2026, and the dividend continued to grow after Kenvue (KVUE) was spun off in 2023. JNJ retained the pharmaceutical and MedTech businesses, which generate the cash flow underpinning the dividend.

What exactly is in JNJ after the Kenvue spinoff?

After spinning off the consumer health segment (Band-Aid, Tylenol, Neutrogena, Listerine) into Kenvue, JNJ now operates two segments: Innovative Medicine (pharmaceuticals like Darzalex, Erleada, Stelara, Tremfya) and MedTech (orthopedic devices, cardiovascular products, surgical robotics, and vision care). These are higher-margin businesses than consumer health.

How serious is the talc litigation risk for JNJ's dividend?

The talc-related lawsuits are JNJ's most prominent legal risk. JNJ has been working through a legal resolution process since the Kenvue spinoff. While settlement costs could be substantial, JNJ's free cash flow runs around $15 billion+ annually, which provides a large buffer. Most analysts consider the litigation a one-time cost risk rather than a structural threat to the dividend.

What is the patent cliff risk for JNJ?

Stelara, one of JNJ's top-selling drugs, faced biosimilar competition beginning in 2023–2024 as its patents expired. This creates a revenue headwind. JNJ's pipeline includes new drugs across oncology, immunology, and neuroscience to replace lost Stelara revenue — but the transition period creates earnings uncertainty.

Are JNJ dividends qualified or ordinary income?

JNJ dividends are qualified dividends for US investors, taxed at the favorable 0%, 15%, or 20% long-term capital gains rate. This is more tax-efficient than REIT or BDC distributions, which are largely ordinary income.

Should I hold JNJ in a taxable account or an IRA?

Because JNJ pays qualified dividends, it is relatively tax-efficient in a taxable brokerage account. Many investors hold JNJ in taxable accounts without significant tax drag. By contrast, REITs (which pay ordinary income) are generally better suited for IRAs. That said, there's nothing wrong with holding JNJ in an IRA too.

Johnson & Johnson (JNJ): Dividend King Review 2026

When you think about investing in healthcare, one company has defined the standard for dividend stability longer than any other: Johnson & Johnson (NYSE: JNJ). With over 60 consecutive years of dividend increases, JNJ has navigated cancer drug approvals, product recalls, massive legal settlements, a global pandemic, and now a major corporate restructuring — all while continuing to raise its quarterly payout.

The 2023 spinoff of the consumer health segment into Kenvue (NYSE: KVUE) was the most significant strategic shift in decades. Understanding what JNJ looks like after that spinoff is essential for any dividend investor evaluating the stock today.

Quick Summary

Home insurance guide →

Income tax filing guide →

Factor	Detail
Ticker	NYSE: JNJ
Sector	Healthcare (Pharma + MedTech)
Dividend Frequency	Quarterly
Consecutive Dividend Increases	60+ years
Dividend Status	Dividend King
2026 Yield (approx.)	~3–4%
Key Businesses	Innovative Medicine, MedTech
Primary Risk	Talc litigation, Stelara patent cliff

Business Model Post-Kenvue: What JNJ Is Now

Coca-Cola (KO): The Other Dividend King to Compare →

The Spinoff in Plain English

Before 2023, JNJ had three segments: Consumer (over-the-counter health brands), Pharmaceuticals, and Medical Devices. In 2023, the consumer segment — home to Band-Aid, Tylenol, Neutrogena, Aveeno, and Listerine — became Kenvue, an independent publicly traded company.

JNJ shareholders received shares of Kenvue pro-rata. JNJ retained two segments:

1. Innovative Medicine (formerly Pharmaceuticals)

This is now JNJ’s largest segment by revenue and easily its highest-margin business:

Oncology: Darzalex (multiple myeloma), Erleada (prostate cancer), Carvykti (CAR-T cell therapy)
Immunology: Stelara (Crohn’s, psoriasis), Tremfya (psoriasis)
Neuroscience: Spravato (treatment-resistant depression)
Infectious disease, cardiovascular, and pulmonary hypertension treatments

2. MedTech (formerly Medical Devices)

Orthopedics: DePuy Synthes (joint reconstruction, spine, trauma)
Cardiovascular: Abiomed (heart pump technologies)
Surgical robotics: Ottava platform (in development, competing with Intuitive Surgical’s da Vinci)
Vision: Johnson & Johnson Vision Care (Acuvue contact lenses, refractive surgery)

Why the Post-Spinoff JNJ May Actually Be Better

The spinoff removed a large, lower-margin business and concentrated JNJ on pharmaceuticals and medical devices — which have higher operating margins, stronger pricing power, and better long-term growth prospects. The post-spinoff JNJ has:

Higher free cash flow margin
A more focused drug development pipeline
Reduced exposure to consumer product litigation (separate from the talc issue)

For a broader perspective on how pharmaceutical dividend stocks compare with other dividend sectors, see our global dividend stocks guide.

Dividend History and Safety

DRIP Strategy 2026: Compound JNJ Dividends Over Decades →

The 60-Year Record

JNJ first achieved Dividend King status years ago and has continued extending it:

60+ consecutive years of dividend increases
Dividend growth rate (5-year CAGR): approximately 5–7%
Payout ratio (EPS-based): approximately 40–55% (post-spinoff, as higher-margin pharma drives earnings)
Free cash flow: approximately $15–18 billion annually, comfortably covering dividends and share buybacks

The payout ratio is actually more manageable now than it was when the consumer segment was included — one of the less-discussed benefits of the Kenvue spinoff.

Dividend Safety Assessment

Three factors make JNJ’s dividend remarkably durable:

Healthcare demand is non-cyclical: Patients need medications and surgical devices regardless of economic conditions
Patent protection: Key drugs are protected from generic competition for extended periods
Diversified revenue: JNJ doesn’t depend on a single drug or device — no single product represents an overwhelming percentage of total revenue

Tax Treatment for US Investors

JNJ’s dividends are classified as qualified dividends — the same favorable category as Coca-Cola and most large US corporations. Tax rates are:

0% for investors in the lowest two brackets
15% for most middle-income investors
20% for high earners (plus potential 3.8% net investment income tax for very high earners)

This is far more favorable than REIT or BDC distributions, which are largely ordinary income. JNJ is tax-efficient in both taxable brokerage accounts and retirement accounts. Unlike REITs, there’s no urgent reason to move JNJ out of a taxable account purely for tax optimization.

For a full breakdown of account placement strategy across different dividend types, see our monthly dividend ETF and account strategy guide.

Risks: What Could Go Wrong

Realty Income (O): Monthly Dividends for Contrast →

1. Talc Litigation: The Headline Risk

JNJ faces tens of thousands of lawsuits claiming that its talc-based baby powder was contaminated with asbestos and caused ovarian cancer and mesothelioma. This is JNJ’s most publicized risk factor.

Key facts for investors:

JNJ has been working through a “Texas Two-Step” bankruptcy strategy (using subsidiary LTL Management) to manage litigation, with mixed court outcomes
The Kenvue spinoff somewhat separated the consumer product liability (talc was under consumer health), though JNJ still retains the legal responsibility
Estimated settlement costs have ranged across analyst projections — but JNJ generates enough free cash flow ($15B+/year) to absorb substantial settlements without jeopardizing the dividend

This is not a make-or-break risk for the dividend, but it is a genuine one-time cost risk and source of stock price volatility.

2. Patent Cliff: The Stelara Problem

Stelara (ustekinumab), JNJ’s blockbuster immunology drug for Crohn’s disease and psoriasis, generated roughly $10 billion+ annually at its peak. Biosimilar competitors began launching in 2023–2024 as patents expired, creating significant revenue pressure.

JNJ must replace this revenue with newer drugs. The pipeline is active:

Nipocalimab (autoimmune diseases)
Tremfya (expanding indications)
Carvykti (CAR-T, high-growth oncology)

But the transition creates a multi-year earnings headwind that investors should factor in.

3. Drug Pricing Pressure

The Inflation Reduction Act (IRA) gives Medicare the ability to negotiate prices for select drugs directly. JNJ’s products are subject to these negotiations, which could reduce long-term revenue from its most profitable drugs. This is an industry-wide headwind, not unique to JNJ, but it’s real.

4. MedTech Competition

Surgical robotics is an emerging battleground. Intuitive Surgical’s da Vinci system dominates the market. JNJ’s Ottava platform is in development, and competing successfully will require significant R&D investment and proven clinical outcomes.

Who Should Consider JNJ?

JNJ fits well for investors who:

Want healthcare sector exposure without picking individual drug winners
Prioritize dividend growth over yield: The 3–4% yield plus 5–7% annual growth creates a compelling long-term return
Value stability: JNJ’s beta is consistently below 1.0
Use taxable accounts: The qualified dividend treatment makes it efficient to hold outside an IRA

Less suitable for investors who:

Need high current income: 3–4% is competitive but not extraordinary
Want biotech-style growth: JNJ is a mature, slow-growing business by design
Are concerned about litigation headlines: The talc lawsuits create periodic stock price volatility even when the fundamental dividend trajectory is positive

Tax-Efficient Dividend Investing: JNJ vs REIT Account Placement →

Bottom Line

Johnson & Johnson’s Dividend King status didn’t happen by accident — it reflects a healthcare business with durable demand, pricing power, and exceptional cash generation. The Kenvue spinoff, while headline-grabbing, arguably left JNJ leaner and more focused on its highest-quality assets.

The talc litigation and Stelara patent cliff are real risks worth monitoring. But with $15+ billion in annual free cash flow and a drug pipeline that continues to generate new revenue streams, JNJ’s dividend is as well-supported as any in the S&P 500.